Patents Examined by Mark Halvorson
  • BIN1 expression as a marker of cancer
    Patent number: 10928396
    Abstract: Provided are methods for screening a subject for cancer. The methods involve obtaining a blood sample from the subject and determining a level of Bridging Integrator 1 (BIN1) isoforms comprising exon 12a in the sample. Optionally, the method involves determining a level of 12a+/13? BIN isoform (comprising exon 12a but lacking exon 13) in the sample. An elevated level of 12a+(e.g., 12a+/13?) BIN1 isoforms in the blood sample indicates the subject has cancer. Also provided are methods for determining efficacy of a cancer therapy in a subject and methods of treating cancer. Isolated antibodies that selectively bind human 12a+ BIN1 are also provided as well as kits for determining 12a+/13? BIN1 isoforms.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: February 23, 2021
    Assignee: SARCOTEIN DIAGNOSTICS, LLC
    Inventors: Darryl Steven Shaw, Neil Gavin Shaw
  • Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
    Patent number: 10894987
    Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: January 19, 2021
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell D. Bigner, Chien-Tsun Kuan, Gregory J. Riggins
  • Anti-CSPG4 reagents and methods of treating cancer
    Patent number: 10881711
    Abstract: Embodiments of the present invention provide antibodies, antigen binding portions thereof, and other polypeptides (e.g., CARs), that specifically bind to CSPG4, an antigen expressed on cancer cells. Monoclonal antibodies, antibody-drug conjugates, and/or CAR-T-cells that specifically bind to CSPG4 positive cancer cells are also provided.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: January 5, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Soldano Ferrone, Xinhui Wang
  • Tumor vascular marker-targeted vaccines
    Patent number: 10874728
    Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: December 29, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Coukos, Andrea Facciabene
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 10858451
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Y. Chu, Gregory Moore, John Desjarlais
  • Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrence
    Patent number: 10859577
    Abstract: The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis and/or prognosing of triple-negative breast cancer (TNBC). The invention is more particularly based on the finding that specific biomarkers are abberantly expressed in patients suffering from a triple-negative breast cancer recurrence, and are highly related to the aggressiveness of this disease, and thus to survival of said patient.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: December 8, 2020
    Assignees: Institut de Cancerologie de L'Ouest, Universite D'Angers, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Catherine Guette, Mario Campone, Olivier Coqueret, Benjamin Barre
  • Antibodies that target human CD47
    Patent number: 10858442
    Abstract: Provided are isolated antibodies that bind to and block CD47, vectors comprising a nucleic acid molecule encoding an amino acid sequence of the binding molecule, and host cells containing the vectors. Methods of making the antibodies, pharmaceutical compositions containing the antibodies, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, such as in treating diseases including cancer, are also provided.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: December 8, 2020
    Assignee: QLSF BIOTHERAPEUTICS INC.
    Inventors: Aaron Kurtzman, Shihao Chen
  • Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
    Patent number: 10852304
    Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 1, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Andrea Muranyi, Kandavel Shanmugam, Shalini Singh, Yifei Zhu
  • Antibodies that bind EGFR and ErbB3
    Patent number: 10844127
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 24, 2020
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
  • Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
    Patent number: 10837064
    Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: November 17, 2020
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
  • Anti-PCNA monoclonal antibodies and use thereof
    Patent number: 10836818
    Abstract: The present invention provides a monoclonal antibody or an antigen-binding portion thereof having increased binding affinity to cytoplasmic PCNA and blocks its interaction with NKp44. The present invention further provides use of the antibody or an antigen-binding portion thereof in the treatment of diseases associated with elevated expression of NKp44, such as cancer.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 17, 2020
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY I
    Inventor: Ari-Angel Porgador
  • Muscular atrophy-inducing agent using hypometabolism-inducing substance T1AM, and use thereof in treating muscular hypertrophy
    Patent number: 10821086
    Abstract: The present invention relates to: a muscular atrophy-inducing agent containing, as an active ingredient, a hypometabolism-inducing substance selected from the group consisting of 3-iodothyronamine (T1AM), [D-Ala2,D-Leu5] enkephalin (DADLE), 5?-adenosine monophosphate (5?-AMP), and hydrogen sulfide (H2S); a method for preparing a muscular atrophy study model comprising inducing muscular atrophy by administering the muscular atrophy-inducing agent; a study model prepared by the method; a screening method for a drug for preventing or treating muscular atrophy using the same; a composition for preventing or treating muscular hypertrophy; and a composition for facial muscle shrinkage.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: November 3, 2020
    Assignee: UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS
    Inventors: Inho Choi, Kyoungsook Park, Hyun Woo Ju
  • c-Met targeting compound-bioactive material conjugate and use thereof
    Patent number: 10792371
    Abstract: Provided is a conjugate including a c-Met targeting compound and a bioactive material and methods of use of the conjugate.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: October 6, 2020
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Su Young Chae, Sunghyun Kim, Eun Ko, Yun Ju Jeong, Jae Hyun Choi
  • Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
    Patent number: 10781262
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 22, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Stefanie Thommen, Jens Schreiner
  • Methods and systems for predicting drug-response
    Patent number: 10774357
    Abstract: Disclosed herein are methods and systems for determining whether a cell is resistant to one or more drugs. Also, disclosed herein are methods and systems for monitoring the treatment of a cancer patient to determine whether the cancerous cells being treated are resistant to the treatment. Further, disclosed herein are methods and systems for predicting the responsiveness of a cell to a drug. Also, disclosed herein are methods and systems to determine the rate of the efficacy of a chemotherapeutic drug on a cancerous, neoplastic or damaged cells.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: September 15, 2020
    Inventor: Nahid Razi
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10751415
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: August 25, 2020
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Monoclonal antibodies against claudin-18 for treatment of cancer
    Patent number: 10738108
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 11, 2020
    Assignees: Astellas Pharma Inc., TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
    Patent number: 10736950
    Abstract: The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan2,3-di-oxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 11, 2020
    Assignee: Herlev Hospital
    Inventor: Mads Hald Andersen
  • T cell receptors and immune therapy using the same
    Patent number: 10725044
    Abstract: The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: July 28, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Leonie Alten, Sebastian Bunk, Dominik Maurer, Claudia Wagner
  • Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
    Patent number: 10704108
    Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: July 7, 2020
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins